BJMO - volume 10, issue 2, april 2016
L. Duck MD, PhD, J.F. Baurain MD, PhD, C. Kirkove MD, R. Poncin MD, A. Barbeaux MD, V. Malvaux MD, J-C. Verougstraete MD, J-L. Squifflet MD, PhD, M. Luyckx MD
To date, the main treatment of loco-regional uterine cancer is surgery. The benefit of adjuvant treatment depends on the subtype of cancer, stage, and risk factors. We describe here the current evidence-based data supporting the administration of adjuvant treatment after surgery, with a focus on chemotherapy.
Top
